Industry Events Dual-carbon Innovations & Startups Competition Find Investors About Us

Sectors

All investors

114 institutional investors

Stage preference

Types of funds

Raked by

Hillhouse Investment

Investments: 442

Funds: 58

Hillhouse Investment Management Limited was established in 2010. Hillhouse has always been committed to creating sustainable long-term growth, and many world-class entrepreneurs with the same goals are our partners. For more than a decade, we have had the privilege of joining hands with many iconic industry leaders to complete the reshaping of these industries. As a long-term value investor with a global perspective, we focus on building excellent enterprises with high quality and sustainability. Hillhouse an open-ended company engaged in management and investment. As a professional investment management institution, Hillhouse has both US dollar and RMB investment platforms, and the entrusted funds mainly come from global institutional investors with long-term vision, including top university endowments, pension funds, non-profit foundations and family offices. At present, Hillhouse has established offices in Beijing, Hong Kong and Singapore.

Hong Kong
CAS Investment

Investments: 152

Funds: 15

CAS Investment Management Co., Ltd. (abbreviated as CASI)' s controlling shareholder is Chinese Academy of Sciences Holdings Co., Ltd. and has State-owned Assets Supervision and Administration Commission of the State Council and an employee-owned company as shareholders. Its predecessor is the Chinese National Economic Council-CAS Scientific and Technological Promotion & Economic Development Foundation. In 1993, it set up China Scientific and Technological Promotion Investment Company in line with Chinese policies governing foundations. In 2006, it was restructured into a limited liability company and changed to its present name. The key industries invested by CASI include instrumentation and high-end equipment manufacturing, information technology, pharmaceutical chemical industry and new materials, modern service industry, etc., and the company have successively supported more than 300 industrialization projects of scientific and technological achievements. CASI is committed to becoming a leading private equity fund manager in China.

Beijing
DCP Capital

Investments: 22

Funds: 7

DCP is an international private equity investment institution focusing on the Greater China market. In the past 30 years, DCP team has invested in a series of pioneering projects in China's PE industry, and supported many leading Chinese enterprises, such as Ping an, Mengniu Dairy, Haier, CICC, Venus Medtech, Tonghua Dongbao, Oriental Yuhong, Simple Love, Nanfu Battery, COFCO Meat, Sunner Development, Far East Horizon, Hotwon, Hengan Group, Belle International, Modern Farming, etc. With its international investment experience and localized resource networks, DCP has accumulated profound industry expertise and solid post-investment management abilities. Adhering to the concept of value investment, DCP aims to establish a long-term win-win partnership with the invested enterprises and create value for the long-term development of the invested enterprises.

Zhuhai, Guangdong Province
Fosun RZ Capital

Investments: 211

Funds: 16

Fosun RZ Capital, established in 2013, is the only global investment institution under Fosun focusing on technology and new consumption. At the same time, it is also one of the investment institutions with the most industrial resources in China. By using its advantages in industrial resources, Fosun RZ Capital will empower enterprises with ecological resources in four major sectors: health, happiness, wealth and intelligence, promote industrial synergy, and boost the leap-forward and international development of enterprises. Up to now, the total assets managed by Fosun RZ Capital have reached nearly 10 billion yuan, more than 100 enterprises have been invested, and more than 70% of them have received follow-up financing. The company has focused on the investment in high-growth and high-tech enterprises in major global economic growth regions for a long time and realized the seven-place coordinate layout of "taking top technology as the horizontal and emerging markets as the vertical": it not only invests in cutting-edge technological innovation territories such as the United States and Israel, but also rapidly lays out high-growth emerging markets such as China, India and Southeast Asia, creating an influential global industrial innovation ecology.

Beijing
Hankang Capital

Investments: 75

Funds: 13

Hankang Capital (formerly "Shanghai Jianxin Capital") is a venture capital focusing on the biomedical industry. We pay attention to major diseases and major clinical needs, carry out in-depth research, support pioneering companies with first-class team and technology platform in advance, and provide professional insights, experience and resources in product pipeline, team building, application and registration, clinical trials, etc. to promote them to become leading enterprises in the industry as soon as possible. We have invested in Innocare Pharma Limited, Akeso, Chip Screen, Keymed Biosciences, AbbiskoTherapeutics and other industry leading companies. Hankang Capital has won the honors such as "TOP 100 Venture Capital Institutions", "TOP 20 Healthcare Investment Institutions", and "TOP 50 Venture Capital Institutions Recognized by LP in China" for many times.

Shanghai